Dr. Reddy’s Laboratories Partners with Henlius for Biosimilar HLX15
In an exciting new collaboration, Dr. Reddy’s Laboratories, a prominent global pharmaceutical company based in India, is joining forces with Henlius, a specialized biopharmaceutical firm. This partnership focuses on the commercialization of HLX15, an innovative biosimilar candidate designed to target multiple myeloma, a type of cancer that affects plasma cells in the bone marrow.
Highlights of the Collaboration
This collaboration combines Dr. Reddy’s well-established global commercial presence with Henlius’ expertise in developing high-quality biosimilars. The agreement outlines that Henlius will handle the development, manufacturing, and commercial supply of HLX15 while benefiting from a substantial potential compensation package that amounts up to $131.6 million. This figure includes an upfront payment of $33 million, along with additional milestone payments contingent on the product’s progression in the market. Furthermore, Henlius is set to receive royalties based on annual net sales, ensuring both companies have a vested interest in the success of HLX15.
The Significance of HLX15
HLX15 is an advanced, recombinant, fully human anti-CD38 monoclonal antibody injection that will be developed in both intravenous and subcutaneous forms. This biosimilar aims to provide a more accessible treatment option for patients afflicted with multiple myeloma, especially those who have faced barriers to accessing the original therapies, Darzalex® and Darzalex Faspro®.
Statements from Leadership
Erez Israeli, Chief Executive Officer of Dr. Reddy’s, expressed his optimism regarding the partnership, noting that it represents a significant step in the journey towards broader market penetration with biosimilars. Israeli highlighted the continual development of Dr. Reddy’s portfolio within emerging and now regulated markets, underlining the recent successes with pegfilgrastim and bevacizumab. He stated, “This latest collaboration with Henlius marks further progress in our regulated markets journey in biosimilars. We aim to ensure patients receive effective and affordable treatments.”
Dr. Jason Zhu, Executive Director and CEO of Henlius, echoed similar sentiments as he acknowledged the importance of their collaboration in addressing global health demands. He stated, “This partnership will enhance the global competitiveness of both organizations in oncology treatment, ultimately allowing us to reach and support more patients around the world.”
About HLX15
HLX15 has undergone rigorous development to ensure it meets the high standards set forth by global health authorities including the NMPA, EMA, and USFDA. Through extensive analytical similarity assessments and preclinical studies, HLX15 has demonstrated comparability with daratumumab, the current market leader. The successful completion of the Phase 1 clinical study indicates promising pharmacokinetic characteristics and safety profiles, indicating HLX15 is well-positioned for the next phases of clinical research.
Henlius: Focused on Innovative Solutions
Henlius has established itself as a formidable player in the biopharmaceutical space since its inception in 2010. With a commitment to offering affordable and innovative biologic medicines, the company has developed a robust pipeline of products that address pressing health needs, particularly in oncology and autoimmune diseases. With several products already approved both in China and internationally, Henlius is rapidly expanding its footprint in the pharmaceutical industry.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories, listed on multiple stock exchanges including NYSE (RDY), has been a leader in providing not just generics but also biosimilars and over-the-counter medications since its founding in 1984. The company operates with a steadfast commitment to affordable healthcare, focusing extensively on therapeutic areas such as oncology, cardiovascular, and gastrointestinal health. Their innovative pipeline continues to evolve, underscoring their mission of ‘Good Health Can’t Wait’ which puts patients first by ensuring access to necessary medications globally.
Frequently Asked Questions
What is HLX15?
HLX15 is a biosimilar candidate developed by Henlius, targeting the same indications as Darzalex® and Darzalex Faspro®, aimed at treating multiple myeloma.
What roles do Dr. Reddy’s and Henlius have in this partnership?
Dr. Reddy’s will focus on the commercialization of HLX15 in the U.S. and Europe while Henlius will manage development and manufacturing.
How much will Henlius potentially earn from this agreement?
Henlius may receive up to $131.6 million through upfront payments and various milestone payments, as well as royalties on sales.
What are the future plans for HLX15?
After successful Phase 1 studies, further comparative efficacy studies are being planned to progress HLX15 toward market approval.
What is the significance of this collaboration?
This collaboration is significant as it aims to enhance patient access to effective cancer treatments while leveraging both companies' strengths in the global market.
